Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2004. The report primarily addresses corporate governance updates, specifically changes to the Board of Directors and the vesting of Performance Share Plan Awards granted in March 2001.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on equity compensation mechanics and board composition rather than financial performance results.
Material Changes
- Board Composition: Dr. Michele Barzach and Ambassador Donald McHenry are stepping down from the Board of Directors effective at the conclusion of the Annual General Meeting on May 17, 2004. This change follows the implementation of the New Combined Code on Corporate Governance.
- Executive Compensation Vesting: The three-year performance period for awards granted on March 29, 2001, concluded on December 31, 2003. The Remuneration Committee determined that 50% of these awards would vest on February 12, 2004.
- Performance Conditions:
- Total Shareholder Return (TSR): GSK ranked 51st against the FTSE 100 index. As the requirement was to rank at least 50th, no awards subject to this condition vested.
- Earnings Per Share (EPS) Growth: The condition requiring EPS growth (excluding currency and exceptional items) to exceed the UK Retail Price Index by at least nine percentage points was achieved in full.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. Management commentary is limited to Chairman Sir Christopher Hogg thanking departing directors for their service. The document notes specific tax and Medicare liabilities incurred by directors upon the vesting of awards, which necessitated immediate share sales.
Important Facts for Investor Verification
- Verify the impact of the New Combined Code on Corporate Governance on future board composition.
- Confirm the specific EPS growth figures for the 2001-2003 period to validate the vesting of the second performance condition.
- Review the specific share sale transactions by Dr. J-P Garnier, Dr. Tachi Yamada, and Mr. John Coombe to understand the immediate dilution or liquidity effects, though these were sales to meet tax/Medicare liabilities.
- Note that the filing does not contain financial results; investors should refer to the Company's Form 20-F or annual reports for fiscal performance data.